CreativeOne Wealth LLC Acquires 2,948 Shares of Insulet Co. (NASDAQ:PODD)

CreativeOne Wealth LLC grew its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 332.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,835 shares of the medical instruments supplier's stock after buying an additional 2,948 shares during the quarter. CreativeOne Wealth LLC's holdings in Insulet were worth $1,001,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Norges Bank acquired a new stake in Insulet in the 4th quarter valued at about $248,806,000. Raymond James Financial Inc. acquired a new position in Insulet in the fourth quarter worth approximately $69,433,000. Alecta Tjanstepension Omsesidigt bought a new position in shares of Insulet in the fourth quarter valued at $53,184,000. Artisan Partners Limited Partnership lifted its position in shares of Insulet by 24.1% during the 4th quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock valued at $201,073,000 after acquiring an additional 149,524 shares during the last quarter. Finally, Proficio Capital Partners LLC acquired a new position in shares of Insulet in the 4th quarter valued at $28,422,000.

Insider Transactions at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the sale, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. This trade represents a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.47% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. StockNews.com lowered Insulet from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. Royal Bank of Canada initiated coverage on shares of Insulet in a research note on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price target on the stock. Piper Sandler lifted their price objective on Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Raymond James reaffirmed an "outperform" rating and issued a $328.00 target price (up from $294.00) on shares of Insulet in a research report on Friday, February 21st. Finally, Canaccord Genuity Group boosted their price target on Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Insulet currently has an average rating of "Moderate Buy" and a consensus price target of $292.06.

Insulet Price Performance

Shares of NASDAQ PODD traded up $6.66 during mid-day trading on Tuesday, hitting $245.23. 63,487 shares of the stock were exchanged, compared to its average volume of 713,886. The company has a market cap of $17.22 billion, a P/E ratio of 42.25, a PEG ratio of 3.62 and a beta of 1.30. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $289.46. The stock's fifty day simple moving average is $262.47 and its two-hundred day simple moving average is $261.27.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. As a group, analysts forecast that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.